Return to site

Salspera Presents Data on Saltikva (Salmonella-IL2) in Metastatic Pancreatic Cancer at the European Association for Cancer Research 2021 Virtual Conference Defence is the Best Attack: Immuno-Oncology Breakthroughs

OAKDALE, Feb. 18th, 2021 -- Salspera, LLC, a clinical-stage biopharmaceutical company dedicated to the development of microbial based immunotherapies for cancer, yesterday presented an overview of the ongoing Phase II clinical study of Saltikva (Salmonella-IL2) in metastatic pancreatic cancer (NCT04589234) at the European Association for Cancer Research 2021 conference Defence is the Best Attack: Immuno-Oncology Breakthroughs.

Title: A Phase 2 Study of Saltikva (Salmonella-IL2) in Metastatic Pancreatic Cancer

Presenters: Daniel Saltzman, MD PhD; Eddie Moradian, PhD

All Posts
×

Almost done…

We just sent you an email. Please click the link in the email to confirm your subscription!

OK